Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan

Kaohsiung Journal of Medical Sciences

Volumn 22, Issue 6, 2006, Pages 257-265

  Lin, Tsung Hsien ^a   Voon, Wen Chol ^a   Yen, Hsueh Wei ^a   Huang, Chih Hsin ^a   Su, Ho Ming ^a   Lai, Wen Ter ^a   Sheu, Sheng Hsiung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dyslipidemia; Fibrinogen; Fibrinolysis; Niacin; Statin

Indexed keywords

D DIMER; FIBRINOGEN; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULARY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; FEMALE; FIBRINOLYSIS; FLATULENCE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; PERICARDIAL EFFUSION; PHARYNGITIS; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TAIWAN; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 33749468599     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(09)70309-2     Document Type: Article

References (25)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screens of the multiple risk factor intervention trial (MRFIT). JAMA 1986;256:2823-8.
2. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983-6.
3. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36.
4. Briel M, Nordmann AJ, Bucher HC. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and meta-analyses. Curr Opin Lipidol 2005;16:601-5.
5. Canner PL, Berge KG, Wenger NK, et al. For the coronary drug project research group. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
6. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-54.
7. th anniversary review. J Intern Med 2005;258:94-114.
8. Lin TH, Huang CH, Voon WC, et al. The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia. Kaohsiung J Med Sci 2000;16:600-6.
9. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
11. Bays H. Existing and investigational combination drug therapy for high density lipoprotein cholesterol. Am J Cardiol 2002;90:30K-43K.
12. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36-46.
13. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000;139:577-83.
14. Vacek JL, Dittmeier G, Chiarelli T, et al. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol 1995;76:182-4.
15. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
16. Bays HE, Dujovne CA, McGovern ME, et al. Advicor versus other cholesterol-modulating agents trial evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72.
17. Denke MA. Combination therapy. J Manag Care Pharm 2003;9:17-19.
18. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8.
19. McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
20. Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 1987;9:582-4.
21. Patterson DJ, Dew EW, Gyorkey F, et al. Niacin hepatitis. South Med J 1983;76:239-41.
22. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:541-6.
23. Liao JK. Statin therapy: having the good without the bad. Hypertension 2004;43:1171-2.
24. Johansson JO, Egberg N, Asplund-Carlson A, et al. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk 1997;4:165-71.
25. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995;92:767-72.